Novastan approvable letter

Texas Biotech (TXB) received an approvable letter from the FDA for Novastan argatroban synthetic thrombin inhibitor to prevent or treat thrombosis in patients with heparin-induced thrombocytopenia. SmithKline Beecham (LSE:SB; SBH) holds rights to market and co-develop Novastan in the U.S. and Canada. TXB plans to present Phase III data at the American College of Cardiology meeting in March and expects to receive the final approval letter in two months. ...